Trial · NCT02555150
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
NCT02555150, Phase 3, Completed, Rhodes Pharmaceuticals, L.P.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD. Trials, record NCT02555150. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02555150
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
- NCT number
- NCT02555150
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- PRC-063, lisdexamfetamine dimesylate, Placebo
- First posted
- 2015-09-21
- Last updated
- 2017-01-19
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tactical Driving Quotient (TDQ) | At 21 days (Visit 9) | The primary outcome measure will be the Tactical Driving Quotient (TDQ) between treatments. The TDQ is an accumulative effect size across multiple driving variables collected during the driving simulation, including: summed standard deviations of steering, driving off the road, veering across the midline, inappropriate braking while on the open road, missed stop signs, exceeding speed limit, standard deviation of speed, time at stop sign deciding when to turn left and time to complete left turns. A higher TDQ score reflects better driving skill. A TDQ of 100 represents average driving and the standard deviation of normal distribution is 15. The normal range of driving (+/- 1.0 SD) is 85 to 115. A TDQ of less than 100 represents worse than average driving (e.g., a TDQ of 115 represents driving performance 1 SD better than average) and a TDQ of greater than 100 represents better than average driving. |
| Secondary | Number of Participants with Adverse Events | Participants will be followed for the duration of the study, an expected average of 10 weeks | Summary of adverse events reported during the study |
| Secondary | Columbia Suicide Severity Rating Scale (CSSRS) | At one week and nine weeks of the study | A Columbia Suicide Severity Rating Scale (CSSRS) assessment will be administered by the investigator to all study participants |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02555150
GET https://conductscience.org/api/trials/v1/NCT02555150/registered